RBC Says 'Not Enough Clarity on Near-Term Issues Facing' Endo Health; Cuts Target to $25

Loading...
Loading...
RBC analyst Shibani Malhotra recommended against buying Endo Health
ENDP
even though the stock is near a 52-week low. In a research note from earlier, Malhotra said there is not enough clarity on near-term issues facing the company. The largest of these issues is the CEO transition Endo has planned for mid-2013. RBC cut their price target on Endo Health from $29 to $25, citing the uncertainty surrounding the CEO change set for mid-2013. Shares of Endo Health are down more than 4 percent to around $25.20.
Posted In: Analyst ColorPrice TargetAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...